• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一名患有t(5;14)(q33;q24)且对伊马替尼敏感的骨髓增殖性疾病患者中,编码CEP110样中心体蛋白的基因NIN与血小板衍生生长因子受体β(PDGFRB)发生了融合。

NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.

作者信息

Vizmanos José L, Novo Francisco J, Román José P, Baxter E Joanna, Lahortiga Idoya, Larráyoz María J, Odero María D, Giraldo Pilar, Calasanz María J, Cross Nicholas C P

机构信息

Department of Genetics, University of Navarra, Pamplona, Spain.

出版信息

Cancer Res. 2004 Apr 15;64(8):2673-6. doi: 10.1158/0008-5472.can-04-0144.

DOI:10.1158/0008-5472.can-04-0144
PMID:15087377
Abstract

We describe a new PDGFRB fusion associated with a t(5;14)(q33;q24) in a patient with a longstanding chronic myeloproliferative disorder with eosinophilia. After confirmation of PDGFRB involvement and definition of the chromosome 14 breakpoint by fluorescence in situ hybridization, candidate partner genes were selected on the basis of the presence of predicted oligomerization domains believed to be an essential feature of tyrosine kinase fusion proteins. We demonstrate that the t(5;14) fuses PDGFRB to NIN, a gene encoding a centrosomal protein with CEP110-like function. After treatment with imatinib, the patient achieved hematological and cytogenetical remission, but NIN-PDGFRB mRNA remained detectable by reverse transcription-PCR.

摘要

我们描述了一名患有长期嗜酸性粒细胞增多慢性骨髓增殖性疾病的患者中,一种与t(5;14)(q33;q24)相关的新的血小板衍生生长因子受体β(PDGFRB)融合。通过荧光原位杂交确认PDGFRB受累并确定14号染色体断点后,基于预测的寡聚化结构域的存在选择候选伙伴基因,这些结构域被认为是酪氨酸激酶融合蛋白的一个基本特征。我们证明t(5;14)将PDGFRB与NIN融合,NIN是一个编码具有CEP110样功能的中心体蛋白的基因。用伊马替尼治疗后,患者实现了血液学和细胞遗传学缓解,但通过逆转录聚合酶链反应仍可检测到NIN-PDGFRB mRNA。

相似文献

1
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.在一名患有t(5;14)(q33;q24)且对伊马替尼敏感的骨髓增殖性疾病患者中,编码CEP110样中心体蛋白的基因NIN与血小板衍生生长因子受体β(PDGFRB)发生了融合。
Cancer Res. 2004 Apr 15;64(8):2673-6. doi: 10.1158/0008-5472.can-04-0144.
2
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.鉴定和功能表征嗜酸粒细胞相关髓系/淋巴肿瘤中的伊马替尼敏感的 DTD1-PDGFRB 和 CCDC88C-PDGFRB 融合基因。
Genes Chromosomes Cancer. 2014 May;53(5):411-21. doi: 10.1002/gcc.22153.
3
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).KIAA1509是一种与t(5;14)(q33;q32)相关的对伊马替尼敏感的骨髓增殖性疾病中的新型血小板衍生生长因子受体β(PDGFRB)融合伴侣。
Leukemia. 2005 Jan;19(1):27-30. doi: 10.1038/sj.leu.2403548.
4
Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.患者存在 t(5;6)和伊马替尼反应性伴嗜酸性粒细胞增多的骨髓增生性肿瘤,存在CEP85L-PDGFRB 融合基因重现。
Leuk Lymphoma. 2013 Jul;54(7):1527-31. doi: 10.3109/10428194.2012.753544. Epub 2013 Jan 28.
5
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.血小板衍生生长因子受体β重排的慢性骨髓增殖性疾病患者对甲磺酸伊马替尼的反应
N Engl J Med. 2002 Aug 15;347(7):481-7. doi: 10.1056/NEJMoa020150.
6
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.血小板衍生生长因子受体β基因破坏产生的慢性骨髓增殖性疾病中三种新的伊马替尼反应性融合基因的特征分析。
Haematologica. 2007 Feb;92(2):163-9. doi: 10.3324/haematol.10980.
7
p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.在一名患有t(5;15)(q33;q22)且对伊马替尼敏感的嗜酸性粒细胞性骨髓增殖性疾病患者中,p53结合蛋白1与血小板衍生生长因子受体β融合。
Cancer Res. 2004 Oct 15;64(20):7216-9. doi: 10.1158/0008-5472.CAN-04-2005.
8
Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.在对伊马替尼敏感的非典型骨髓增殖性疾病中,PRKG2和SPTBN1与血小板衍生生长因子受体β基因(PDGFRB)的融合。
Cancer Genet Cytogenet. 2008 Feb;181(1):46-51. doi: 10.1016/j.cancergencyto.2007.10.021.
9
KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.KANK1是一种候选抑癌基因,在一种对伊马替尼敏感的伴有严重血小板增多症的髓系肿瘤中与PDGFRB融合。
Leukemia. 2010 May;24(5):1052-5. doi: 10.1038/leu.2010.13. Epub 2010 Feb 18.
10
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.血小板衍生生长因子受体β(PDGFRB)融合基因阳性且BCR-ABL阴性的慢性骨髓增殖性疾病患者对伊马替尼的持久反应。
Blood. 2007 Jan 1;109(1):61-4. doi: 10.1182/blood-2006-05-024828. Epub 2006 Sep 7.

引用本文的文献

1
Aberrant expression of CNTRL was associated with poor prognosis, immune response and progression in glioma.CNTRL的异常表达与胶质瘤的预后不良、免疫反应及进展相关。
Discov Oncol. 2025 May 9;16(1):706. doi: 10.1007/s12672-025-02531-1.
2
PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.一名37岁男性的伴有显著嗜酸性粒细胞增多的血小板衍生生长因子受体β重排的髓系肿瘤;文献综述
Am J Case Rep. 2017 Feb 17;18:173-180. doi: 10.12659/ajcr.900623.
3
Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature.
慢性粒单核细胞白血病中血小板衍生生长因子受体β与CEV14基因的融合:一例报告并文献复习
Oncol Lett. 2016 Jan;11(1):770-774. doi: 10.3892/ol.2015.3949. Epub 2015 Nov 18.
4
JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.JAK2酪氨酸激酶被中心体蛋白Ninein磷酸化并受到其负调控。
Mol Cell Biol. 2015 Jan;35(1):111-31. doi: 10.1128/MCB.01138-14. Epub 2014 Oct 20.
5
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.携带 PDGFRB 融合基因的髓系恶性肿瘤患者使用伊马替尼可获得持久的长期缓解。
Blood. 2014 Jun 5;123(23):3574-7. doi: 10.1182/blood-2014-02-555607. Epub 2014 Mar 31.
6
Primary eosinophilic disorders: a concise review.原发性嗜酸性粒细胞疾病:简要综述。
Curr Hematol Malig Rep. 2008 Jan;3(1):37-43. doi: 10.1007/s11899-008-0007-9.
7
BCR-ABL-negative chronic myeloid leukemia.BCR-ABL 阴性慢性髓性白血病。
Curr Hematol Malig Rep. 2007 May;2(2):75-82. doi: 10.1007/s11899-007-0011-5.
8
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.骨髓增殖性肿瘤中的分子药物靶点:突变型ABL1、JAK2、MPL、KIT、PDGFRA、PDGFRB和FGFR1。
J Cell Mol Med. 2009 Feb;13(2):215-37. doi: 10.1111/j.1582-4934.2008.00559.x. Epub 2008 Oct 23.